Add time:08/03/2019         Source:sciencedirect.com

Background and objectiveUCN-01 (cas 112953-11-4) is a staurosporine analogue shown to abrogate the G2 checkpoint through inhibition of cyclin-dependent kinases. Preclinical evidence suggests synergy between UCN-01 and cytotoxic chemotherapy. Topotecan is an active agent in ovarian cancer. This phase II study was conducted to investigate the safety and efficacy of topotecan and UCN-01 in patients with advanced ovarian cancer.

We also recommend Trading Suppliers and Manufacturers of UCN-01 (cas 112953-11-4). Pls Click Website Link as below: cas 112953-11-4 suppliers